Bain Capital Life Sciences

Activity in this selectionabrdn-686b29d8

By stage

Series C+3

Growth1

Biotech2

Healthtech2

United States3

Australia1

4 in this selection

Aug 18

Develops immunotherapies that selectively deplete cytotoxic T cells to treat autoimmune diseases

$66MSeries D

Role not disclosed

Jul 15

Develops lead-212 targeted alpha therapies to treat cancer

$315MSeries D

Role not disclosed

Jun 4

Develops minimally invasive eShunt System to treat communicating hydrocephalus and other neurological diseases

$85MSeries C

Role not disclosed

Mar 17

Develops treatments for patients suffering from thromboembolic disease

$100MGrowth

Role not disclosed